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revealed that higest/more economic burden was found in male patients (Rs. 
18018), the age group of 51-60 years (Rs. 19184), the newly diagnosed (<1year) 
patients (Rs. 21411), the patients who stayed for 10-13 days in the hospital  
(Rs. 28406), the patients with two co-morbidities (Rs. 18935), the patients with 
agriculture as their occupation (Rs. 22306) and the patients who bearing 
macrovascular complications (Rs. 7706).  
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OBJECTIVES: Nowadays thyroid disease found in 50% of the adult population and 
80% of the elderly population of Ukraine. However there is no information about 
pharmacoeconomic analysis of this pathology. METHODS: We conducted a 
retrospective analysis of medical records of 3417 patients with hypothyroidism 
(n=2143) and diffuse toxic goiter (DTG) (n=1274), and determined the total annual 
cost of illness (COI) including direct and indirect costs. RESULTS: 12-month COI 
of hypothyroidism was $1860681.18, similar costs of DTG was $1439632.74. 
Annual direct costs of treatment per patient with hypothyroidism were $229.10, 
of which costs of investigations accounted for $62.28 (27.18%), the cost of 
medicinal treatment of the underlying disease was $27.96 (12.20%) and the cost 
of medicinal treatment of complications associated with hypothyroidism was 
$138.86 (60.62%). An indirect cost of treatment per patient with hypothyroidism 
was $639.16. The total 12-month COI of hypothyroidism per patient was $868.26. 
The total 12-month COI of DTG per patient was $1130.01, of which indirect costs 
accounted for $746.44. Annual direct costs of treatment per patient with DTG 
were $383.57, of which costs of investigations accounted for $109.50 (28.55%), the 
cost of medicinal treatment of the underlying disease was $100.45 (26.19%) and 
the cost of medicinal treatment of complications associated with DTG was 
$173.62 (45.26%). CONCLUSIONS: Thus, first held in Ukraine cost of illness 
analysis of the thyroid disease showed that the most money spent on indirect 
costs.  
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OBJECTIVES: The study objective was to provide current patient-level paid cost 
estimates for complications among adult patients with Type 2 diabetes. 
METHODS: Patients ages ≥18 with ≥1 claim for a diabetes-related complication 
were selected from the PharMetrics Health Plan Claims Database, a large U.S. 
claims database including medical and pharmacy claims for >75 million patients 
from 80 health plans, during 2009-2010. Patients were continuously-enrolled in 
the same health plan ≥12 months before and ≥24 months after the first 
complication claim and had a diagnosis of Type-2 DM prior to their first 
complication. Patients with gestational diabetes, missing cost, or Medicare 
Reimbursement or SCHIP coverage were excluded. Diabetes-related 
complications included cardiovascular events, gangrene, amputation, foot ulcer, 
renal disease, chronic kidney disease, eye disease and neuropathy. All direct 
costs in the 2-years following complications were inflated to 2011 dollars. 
RESULTS: There were 113,222 adult Type-2 DM patients identified with a mean 
age of 58 years and 53% male. The most frequent complications included 
neuropathy (27%), non-proliferative retinopathy (22%), renal disease (21%) and 
heart failure (14%). The most frequent treatments were oral antidiabetics (69%), 
antihyperlipidemics (62%), ACE-inhibitors (44%), insulins (34%) and 
antidepressants (29%). The mean (SD) total cost per patient was $38,849 ($71,253) 
[inpatient $14,086 ($45,290), outpatient $17,319 ($40,887), and pharmacy $7,443 
($12,152)]. Renal disease cost among those with renal disease averaged $20,908 
($80,294), foot ulcers costs among those with amputation/foot ulcers averaged 
$6,358 ($18,017) and heart failure costs among those with cardiovascular/ 
cerebrovascular disease averaged $5,764 ($24,384). CONCLUSIONS: Patients with 
Type 2 DM exhibited substantial health care costs associated with medical 
complications. The most costly conditions are renal disease, foot ulcers/ 
amputations and cardiovascular/cerebrovascular diseases.  
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OBJECTIVES: To compare health care costs among patients with bone metastasis 
secondary (BMS) to prostate cancer (PC) compared to a matched cohort of 
patients with PC without BM. METHODS: A retrospective analysis was performed 
using the OPTUMInsight Oncology claims database. Male patients aged ≥18 years, 
with BMS to PC between July 1, 2003 and December 31, 2011, who were insured 
by a commercial health plan were identified (first BM termed “index”). Patients 
were required to have > 6 months continuous eligibility prior to and > 6 months 
subsequent to the first PC diagnosis in the index period (January 1, 2004 - June 
30, 2010). Patients with a diagnosis of BMS to PC were identified and matched 1:1 
to PC patients without BM based on age, geographic region, payer type and year 
of study entry (index year). Patients were followed from index to death or 
database end. Study measures included health care costs. RESULTS: A total of 
1900 patients with BMS to PC were matched to 1890 PC patients without BM. 
Among those patients with BMS to PC versus those PC patients without BM, 
respectively, the mean (SD) annualized total follow-up costs per patient were 
$69,517 ($77,127) and $21,364 ($29,994). The largest proportion of mean costs 
were attributable to all other medical costs in the BMS to PC cohort (29.5%), 
followed by outpatient visits (26.4%), inpatient hospitalizations (25.9%), and total 
pharmacy costs (18.1%). Among the PC patients without BM cohort the largest 
proportion of mean costs were inpatient hospitalizations (29.6%), followed by all 
other medical costs (28.9%), outpatient visits (27.6%), and total pharmacy costs 
(12.6%). CONCLUSIONS: Patients with BMS to PC had 3.25 fold more costs 
compared to the PC patients without BM, mainly driven by inpatient and 
outpatient costs. This indicates a substantial economic burden incurred by 
patients with BMS to PC.  
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OBJECTIVES: To describe the direct medical costs associated with management 
of hospital admission due to heart failure. METHODS: Cohort study of patients 
hospitalized due to heart failure during 2009 and 2010. 1426 patients with heart 
failure hospitalized in two tertiary care hospitals in Bogota that manage mainly 
patients from the Colombian contributive obligatory health care plan (workers 
and their families). All patients with a discharge diagnosis of heart failure during 
the time of the study were included. The point of view of the study was that of 
the third-party payer. Bills for each patient´s costs of care sent and accepted by 
the third party payer were quantified and broken down by cost source.  
Costs were adjusted to Colombian pesos of 2011 (US$1= COL $1,794). RESULTS: 
The hospital bills of 1426 discharged patients (352 in one hospital and 1074 in the 
second hospital) were analyzed. The mean costs associated with an event of 
hospitalization, adjusted to 2011, was COL$ 10,400,213 (SD COL$ 22,552,954; 
median 3,171,129; IQ Range: 1,506,654-6,802,384). Out of this total cost, 32,8% (SD 
20.9%) corresponded to medication costs; 26.1% (SD. 15,5%) to hospital  
stay; 13,1% (SD 12,9%) to medical fees; 12,5% (SD 9,8%) to laboratory tests, and 
18,7% (SD 13,4%) to other costs. CONCLUSIONS: Hospitalizations costs in 
Colombia due to heart failure are substantial and highly variable, when 
compared with those for other conditions. The main driver of these costs is 
medication use. This study should set the basis for the estimation of the cost-
effectiveness of interventions that decrease the rate of hospitalization or the 
length of stay of these patients.  
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OBJECTIVES: To evaluate the resource use and associated costs of patients 
treated for polycythemia vera (PV), myelofibrosis (MF) and essential 
thrombocythemia (ET) in the Brazilian public health care system. METHODS: 
DATASUS is a Brazilian comprehensive database that reports all outpatient and 
inpatient services provided by the Brazilian public health care system. Patients 
identified with the diagnosis of PV (ICD 10 D45), MF (D47.1) and ET (D47.3) in the 
Datasus database between January 2010 and December 2010 were included in the 
analysis, irrespective of the date of diagnosis. Patients’ profile was defined based 
on age, sex and geographical region. Costs and resource use patterns were 
analyzed for the year 2010 and characterized by the percentage of patients using 
each health resource, the average quantity per patient and the total associated 
cost. Analyses were segmented by outpatient (drugs and transport) and inpatient 
(hospitalization) costs. RESULTS: The number of patients identified with the 
diagnosis of PV, MF and ET were 1533, 2130 and 2413, respectively. Their average 
age was 65, 63 and 63 years, and the percentage of females equaled 55%, 55% and 
66%, respectively. The majority of patients live in the southeast region of Brazil. 
The three diseases present a similar treatment pattern. The majority of 
outpatient costs are associated to first line and second line chemotherapy 
treatment (21.9% and 77.5% for PV; 12.6% and 86.9% for MF; 12.6% and 87.2% for 
ET, respectively). The average annual outpatient and inpatient costs per patient 
were: R$2,581.27 and R$15.27 for PV; R$3,341.02 and R$45.22 for MF; R$ 4,070.28 
and R$15.92 for ET) (1 USD = R$2.04). CONCLUSIONS: The current treatment for 
PV, MFand ET in the Brazilian public health care system relies basically on the 
use of first and second line chemotherapy. These items are responsible for more 
than 90% of the annual treatment cost.  
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OBJECTIVES: Lifestyle intervention is effective in reducing the risk of 
hypertension and diabetes. Previous studies suggested such an intervention, if 
targeted to persons with prediabetes alone (defined by HbA1c of 5.7-6.3% or 
fasting plasma glucose of 110-125 mg/dL), was cost-saving but would take more 
than 20 years to recoup the intervention costs. Health plans typically have much 
shorter planning horizons. Therefore, a more selective population might be 
